Daily close, T-120 (10/11/24) through T+5. Run-up high $300.55 on 10/24/24, low $232.27 on 11/26/24 (T-120 to T-1). FDA decision 3/28/25. Historical price action, not a forecast.
Positioning before the decision
On Mar 14, 2025, 14 days before the decision date, at-the-money options priced a move of ±15.0% through Apr 17, 2025 (the first listed expiry after the decision; ATM implied volatility 62%). The stock closed -0.9% at the first close across the decision and -3.3% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was Qfitlia (fitusiran) - (ATLAS) approved by the FDA?
Yes. The FDA approved the application for Qfitlia (fitusiran) - (ATLAS) on March 28, 2025. The primary source is linked on this page.
What was Qfitlia (fitusiran) - (ATLAS) under FDA review for?
The application covered Hemophilia A/B. The FDA approved the application on March 28, 2025.
How did ALNY stock react to the FDA decision?
On the decision day ALNY moved -0.9%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.